8-K: Ernexa Therapeutics Changes Auditors Amidst Going Concern Warning and Material Weakness Disclosure

Ernexa Therapeutics Inc. has dismissed Grant Thornton LLP and appointed Haskell & White LLP as its new independent registered public accounting firm, following previous audit reports that included a going concern explanatory paragraph and a disclosed material weakness in internal controls.

Summary

• Ernexa Therapeutics Inc. dismissed Grant Thornton LLP as its independent registered public accounting firm on June 30, 2025.
• The Audit Committee of the Board of Directors approved the dismissal.
• Grant Thornton had performed audits of the company's consolidated financial statements for the years ended December 31, 2024 and 2023.
• Grant Thornton's reports for these years included an explanatory paragraph describing that substantial doubt was raised as to the Company's ability to continue as a going concern.
• There were no disagreements with Grant Thornton on accounting principles, financial statement disclosure, or auditing scope, nor any reportable events, except for a material weakness in the Company's internal control over financial reporting as of and for the year ended December 31, 2023.
• This material weakness stemmed from a lack of technical accounting proficiency in complex matters.
• On July 1, 2025, the Company engaged Haskell & White LLP as its new independent registered public accounting firm, a decision also approved by the Audit Committee.
• Neither the Company nor anyone acting on its behalf consulted Haskell & White regarding accounting principles or audit opinions prior to their engagement.

Sentiment

Score: 3

Explanation: The presence of a "going concern" warning and a "material weakness" in internal controls are significant negative indicators, outweighing the procedural aspects of the auditor change and the lack of other disagreements. These issues point to fundamental financial and operational challenges.

Positives

• No disagreements on accounting principles, financial statement disclosure, or auditing scope were reported between the Company and Grant Thornton.
• The Audit Committee of the Board of Directors approved both the dismissal of Grant Thornton and the engagement of Haskell & White, indicating proper governance procedures were followed for the auditor change.

Negatives

• Grant Thornton's audit reports for the years ended December 31, 2024 and 2023 included an explanatory paragraph raising substantial doubt about the Company's ability to continue as a going concern.
• A material weakness in the Company's internal control over financial reporting was identified as of and for the year ended December 31, 2023.
• The material weakness was attributed to a lack of technical accounting proficiency in complex matters.

Risks

• Substantial doubt exists regarding the Company's ability to continue as a going concern, as noted in Grant Thornton's audit reports for 2023 and 2024.
• A material weakness in internal control over financial reporting was identified for the year ended December 31, 2023, specifically due to a lack of technical accounting proficiency in complex matters, which could lead to future financial reporting errors.

Future Outlook

No explicit forward-looking statements or guidance are provided in the document. The filing focuses on a past event (auditor change) and its immediate context.

Management Comments

• "We have read Item 4.01 of Form 8-K of Ernexa Therapeutics Inc. dated June 30, 2025, and agree with the statements concerning our Firm contained therein." (Grant Thornton LLP, in their letter to the SEC)

Industry Context

Changes in independent registered public accounting firms are common occurrences for publicly traded companies, often driven by factors such as cost, service quality, or strategic alignment. However, when such changes occur in the context of a "going concern" warning and a "material weakness" in internal controls, it signals heightened scrutiny and potential underlying financial or operational challenges for the company, which is a significant concern in the biotech/pharma industry where capital is crucial.

Comparison to Industry Standards

• The disclosure of a "going concern" explanatory paragraph in audit reports is a serious red flag, indicating that the auditor has substantial doubt about the company's ability to continue operating for at least one year. This is a significant deviation from the standard clean audit opinion expected of healthy public companies.
• The identification of a "material weakness in internal control over financial reporting," particularly one stemming from a "lack of technical accounting proficiency in complex matters," suggests a deficiency in the company's financial infrastructure that is below industry best practices for public companies. Robust internal controls are fundamental for reliable financial reporting and investor confidence.
• While auditor changes themselves are not unusual, the specific reasons (going concern, material weakness) place Ernexa Therapeutics Inc. in a less favorable light compared to peers with clean audit opinions and effective internal controls. For example, a well-established biotech company like Amgen or Gilead Sciences would typically have strong internal controls and no going concern issues.

Corporate Governance

Stakeholder Impact

• Shareholders: Likely negative impact due to the "going concern" warning and "material weakness," which could lead to decreased investor confidence and potential share price decline.
• Creditors: May face increased risk due to the "going concern" warning, potentially affecting lending terms or willingness to extend credit.
• Management/Employees: The material weakness in internal controls suggests a need for improved financial reporting processes and potentially additional training or personnel in accounting.

Next Steps

• The Company will need to address the material weakness in its internal control over financial reporting.
• The Company will need to demonstrate its ability to continue as a going concern to alleviate auditor concerns in future reports.

Key Dates

Recommendation

Keywords

Ernexa Therapeutics, Auditor change, Grant Thornton, Haskell & White, Going concern, Material weakness, Internal control over financial reporting, SEC filing, Form 8-K, Public accounting firm, Financial reporting, Corporate governance